Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma.
Journal Article (Journal Article;Review)
Angiogenesis, the growth of new blood vessels from previously existing vasculature, is a requirement for tumor growth and metastasis. The first US FDA-approved drugs targeting angiogenesis have shown potential in the treatment of malignant gliomas. Immunotherapy as a treatment modality lends itself well to specifically targeting angiogenesis in tumors and may represent a powerful tool in the treatment of malignant gliomas. This review focuses on developments in immunotherapy targeting angiogenesis and tumor-vascular-specific endothelial cells using a variety of immunotherapeutic strategies including monoclonal antibodies and conjugated immunotoxins, as well as cellular, peptide, DNA and dendritic cell vaccines.
Full Text
Duke Authors
- Bigner, Darell Doty
- Desjardins, Annick
- Friedman, Allan Howard
- Friedman, Henry Seth
- Gromeier, Matthias
- Sampson, John Howard
Cited Authors
- Everson, RG; Graner, MW; Gromeier, M; Vredenburgh, JJ; Desjardins, A; Reardon, DA; Friedman, HS; Friedman, AH; Bigner, DD; Sampson, JH
Published Date
- May 2008
Published In
Volume / Issue
- 8 / 5
Start / End Page
- 717 - 732
PubMed ID
- 18471045
Electronic International Standard Serial Number (EISSN)
- 1744-8328
Digital Object Identifier (DOI)
- 10.1586/14737140.8.5.717
Language
- eng
Conference Location
- England